J.P. Morgan Sticks to Its Buy Rating for BioMarin


J.P. Morgan analyst Cory Kasimov maintained a Buy rating on BioMarin (NASDAQ: BMRN) on June 18. The company’s shares opened today at $95.94.

According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.9% and a 38.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Jounce Therapeutics Inc, and Bluebird Bio.

Currently, the analyst consensus on BioMarin is Strong Buy and the average price target is $117.18, representing a 22.1% upside.

In a report issued on June 15, Wedbush also reiterated a Buy rating on the stock with a $115 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $100.03 and a one-year low of $75.81. Currently, BioMarin has an average volume of 1.36M.

Based on the recent corporate insider activity of 104 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BMRN in relation to earlier this year. Earlier this month, Jean Jacques Bienaime, the CEO of BMRN bought 1,000 shares for a total of $14,390.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include BioMarin, Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts